Is ZimVie, Inc. overvalued or undervalued?

As of 10 August 2022, the valuation grade for ZimVie, Inc. moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 0.66, an EV to EBITDA of 11.89, and an EV to Sales ratio of 0.95, which suggest that the stock may not justify its price given its financial performance.
In comparison to its peers, ZimVie, Inc. has a notably high EV to EBIT ratio of 419.62, while AngioDynamics, Inc. has a significantly lower EV to EBITDA of 226.06, highlighting a stark contrast in valuation. Additionally, the company's recent stock performance shows a year-to-date return of 35.48%, which outperforms the S&P 500's 12.22% return, but its longer-term performance over three years (42.32% vs. 70.41%) indicates that it has lagged behind the benchmark.